Dermata Therapeutics, Inc.
DRMANASDAQHealthcare● Active
$1.21
+$0.03(+2.54%)
Market Cap$824684
P/E Ratio—
52W High$8
52W Low$1.1
Dermata Therapeutics, Inc. (DRMA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DRMA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.48
Est. -$0.53 · +9.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
DRMA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$0.55 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.53 | -$0.48 | +9.4% | — | — | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$1.54 | -$1.52 | +1.3% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$1.59 | -$1.65 | -3.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$2.90 | -$1.66 | +42.8% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.45 | -$4.50 | -900.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 17, 2025 | -$1.50 | -$3.15 | -110.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$2.64 | -$2.04 | +22.7% | — | — | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$0.55
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.48
EPS Est.
-$0.53
EPS Surpr.
+9.4%
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$1.52
EPS Est.
-$1.54
EPS Surpr.
+1.3%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$1.65
EPS Est.
-$1.59
EPS Surpr.
-3.8%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$1.66
EPS Est.
-$2.90
EPS Surpr.
+42.8%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$4.50
EPS Est.
-$0.45
EPS Surpr.
-900.0%
Revenue
—
Q1 FY2025
Mar 17, 2025Miss
EPS Actual
-$3.15
EPS Est.
-$1.50
EPS Surpr.
-110.0%
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$2.04
EPS Est.
-$2.64
EPS Surpr.
+22.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Q3 FY2026 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Q2 FY2026 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q1 FY2026 | $-0.53 | $-0.53 | $-0.53 | 1 |
| Q4 FY2025 | $-1.54 | $-1.54 | $-1.54 | 1 |
| Q3 FY2025 | $-1.59 | $-1.59 | $-1.59 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +9.4% | $1.24 | $1.19 | -4.03% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +1.3% | $1.46 | $1.37 | -6.16% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -3.8% | $3.14 | $3.07 | -2.23% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +42.8% | $6.11 | $6.45 | +5.56% |
| ▼ Q2 FY2025 | May 14, 2025 | -900.0% | $7.80 | $7.79 | -0.13% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -110.0% | $11.90 | $11.70 | -1.68% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +22.7% | $12.90 | $12.30 | -4.65% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -10.3% | $23.70 | $23.30 | -1.69% |
Q2 FY2026-4.03%
Report Date
May 13, 2026
EPS Beat/Miss
+9.4%
Price Before
$1.24
Price After
$1.19
Q1 FY2026-6.16%
Report Date
Mar 26, 2026
EPS Beat/Miss
+1.3%
Price Before
$1.46
Price After
$1.37
Q4 FY2025-2.23%
Report Date
Nov 14, 2025
EPS Beat/Miss
-3.8%
Price Before
$3.14
Price After
$3.07
Q3 FY2025+5.56%
Report Date
Aug 13, 2025
EPS Beat/Miss
+42.8%
Price Before
$6.11
Price After
$6.45
Q2 FY2025-0.13%
Report Date
May 14, 2025
EPS Beat/Miss
-900.0%
Price Before
$7.80
Price After
$7.79
Q1 FY2025-1.68%
Report Date
Mar 17, 2025
EPS Beat/Miss
-110.0%
Price Before
$11.90
Price After
$11.70
Q4 FY2024-4.65%
Report Date
Nov 13, 2024
EPS Beat/Miss
+22.7%
Price Before
$12.90
Price After
$12.30
Q3 FY2024-1.69%
Report Date
Aug 7, 2024
EPS Beat/Miss
-10.3%
Price Before
$23.70
Price After
$23.30
Avg Beat Reaction-2.32%
Avg Miss Reaction-1.43%
Beat Rate4 / 8 quarters
Largest Move-6.16% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DRMA ends December
Dermata Therapeutics, Inc. (DRMA) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.48 — beating the analyst consensus of $-0.53 by +9.4%. DRMA has beaten EPS estimates for 2 consecutive quarters. The next DRMA earnings date is expected around September 1, 2026.
Each quarter, investors track DRMA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DRMA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DRMA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DRMA earnings · 5 questionsDermata Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. DRMA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DRMA historically reports after market close (AMC).
DRMA earnings datewhen is DRMA earningsDRMA next earnings datewhen does DRMA report earningsDRMA earnings calendar
▸ Source: FMP · Dermata Therapeutics, Inc. SEC filings · US GAAP · Dermata Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026